OIS Podcast | Ophthalmology's leading Podcast - Graybug Vision – Flush with Cash – Is Making Big Moves to Change its Approach to Finding New Treatments for Wet AMD & Other Eye Disease

Graybug Vision – Flush with Cash – Is Making Big Moves to Change its Approach to Finding New Treatments for Wet AMD & Other Eye Disease

05/03/16 • 14 min

OIS Podcast | Ophthalmology's leading Podcast

Graybug interim CEO Jeff Cleland shares details on the company’s $44.5 million Series B. Cleland gives a report on investor appetite for ophthalmology companies. He also explains how the firm would use the capital to shift its approach from a drug delivery platform technology company to a drug maker.

Previous Episode

Sun Ophthalmics Looks to Build a Brand-New Business in the US

Sun Pharma, the fifth largest pharma company in the US, targeted ophthalmology as one of the first planks in its new branded pharma business. Hear ophthalmology veteran Jerry St. Peter explain how Sun Ophthalmics hopes to build a new team in ophthalmology.

Next Episode

What the Heck Happened at OIS@ASCRS?

The fifth OIS@ASCRS delivered highlights on diagnostics, glaucoma devices, and What The Future of ophthalmology might bring. OIS Podcasts will provide a quick review of the day for those who couldn’t make it (or simply had overstuffed their meeting calendar in New Orleans).